.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Fish and Richardson
Chinese Patent Office
QuintilesIMS
Fuji
US Department of Justice
Harvard Business School
McKesson
Mallinckrodt
Teva

Generated: June 29, 2017

DrugPatentWatch Database Preview

Claims for Patent: 4,430,343

« Back to Dashboard

Claims for Patent: 4,430,343

Title: Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same
Abstract:Novel benzimidazole derivatives of the formula: ##STR1## wherein R.sup.1 is an alkyl group having 1 to 3 carbon atoms, allyl group, propargyl group, or phenyl group; R.sup.2 is hydrogen atom or an alkyl group having 1 to 3 carbon atoms; and n is 2 or 3, or pharmaceutically acceptable acid addition salts thereof, which have excellent antihistaminic activities and are useful as antiallergics for various allergic diseases, and a process for the preparation thereof, and an antihistaminic composition containing the compound as an active ingredient.
Inventor(s): Iemura; Ryuichi (Kawanisi, JP), Kawashima; Tsuneo (Kobe, JP), Fukuda; Toshikazu (Osaka, JP), Ito; Keizo (Osaka, JP), Nose; Takashi (Nara, JP), Tsukamoto; Goro (Toyonaka, JP)
Assignee: Kanebo, Ltd. (Tokyo, JP)
Application Number:06/436,032
Patent Claims: 1. A benzimidazole derivative of the formula: ##STR20## wherein R.sup.1 is an alkyl group having 1 to 3 carbon atoms, allyl group, propargyl group, or phenyl group; R.sup.2 is hydrogen atom or an alkyl group having 1 to 3 carbon atoms; and n is 2 or 3, or a pharmaceutically acceptable acid addition salt thereof.

2. A compound according to claim 1 which is 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole or a pharmaceutically acceptable acid addition salt thereof.

3. A compound according to claim 1 which is 1-[2-(propargyloxy)ethyl]-2-(4-methyl-1-piperazinyl)benzimidazole or a pharmaceutically acceptable acid addition salt thereof.

4. A compound according to claim 1 which is 1-[2-(ethoxy)ethyl]-2-(1-piperazinyl)benzimidazole or a pharmaceutically acceptable acid addition salt thereof.

5. A compound according to claim 1 which is 1-[2-(phenoxy)ethyl]-2-(4-methyl-1-piperazinyl)benzimidazole or a pharmaceutically acceptable acid addition salt thereof.

6. An antihistaminic composition, which comprises an effective amount of a benzimidazole derivative of the formula: ##STR21## wherein R.sup.1 is an alkyl group having 1 to 3 carbon atoms, allyl group, propargyl group, or phenyl group; R.sup.2 is hydrogen atom or an alkyl group having 1 to 3 carbon atoms; and n is 2 or 3, or a pharmaceutically acceptable acid addition salt thereof as an active ingredient in admixture with a conventional pharmaceutically acceptable carrier or diluent.

7. The composition according to claim 6, wherein the active ingredient is 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole or a pharmaceutically acceptable acid addition salt thereof.

8. The composition according to claim 6, wherein the active ingredient is 1-[2-(propargyloxy)ethyl]-2-(4-methyl-1-piperazinyl)benzimidazole or a pharmaceutically acceptable acid addition salt thereof.

9. The composition according to claim 6, wherein the active ingredient is 1-[2-(ethoxy)ethyl]-2-(1-piperazinyl)benzimidazole or a pharmaceutically acceptable acid addition salt thereof.

10. The composition according to claim 6, wherein the active ingredient is 1-[2-(phenoxy)ethyl]-2-(4-methyl-1-piperazinyl)benzimidazole or a pharmaceutically accetpable acid addition salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Express Scripts
Argus Health
Cerilliant
US Army
Chinese Patent Office
Cipla
Novartis
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot